​

Editas Medicine (EDIT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

EDIT Stock Forecast

Editas Medicine (EDIT) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $8.00, with a high of $10.00 and a low of $5.00. This represents a 529.92% increase from the last price of $1.27.

$1 $3 $5 $7 $9 $11 High: $10 Avg: $8 Low: $5 Last Closed Price: $1.27

EDIT Stock Rating

Editas Medicine stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (57.89%), 6 Hold (31.58%), 2 Sell (10.53%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 2 6 11 Strong Sell Sell Hold Buy Strong Buy

EDIT Price Target Upside V Benchmarks

TypeNameUpside
StockEditas Medicine529.92%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--7
Avg Price Target--$9.29
Last Closing Price$1.27$1.27$1.27
Upside/Downside--631.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25-49-215
Mar, 25-49-215
Feb, 25-49-215
Jan, 25-412-218
Dec, 24-914-225
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Gena WangBarclays$5.00$3.1260.26%293.70%
Oct 23, 2024Yanan ZhuWells Fargo$9.00$3.29173.56%608.66%
Oct 22, 2024Joel BeattyRobert W. Baird$10.00$3.29203.95%687.40%
Aug 08, 2024Joon LeeTruist Financial$12.00$4.24183.02%844.88%
Aug 08, 2024Greg HarrisonBank of America Securities$15.00$4.21256.29%1081.10%
May 30, 2024Liisa BaykoEvercore ISI$7.00$5.1037.25%451.18%
May 09, 2024Matthew HarrisonMorgan Stanley$7.00$5.0438.89%451.18%
Sep 28, 2023Dae Gon HaStifel Nicolaus$17.00$6.92145.66%1238.58%
Dec 13, 2022Citigroup$11.00$9.9610.44%766.14%
Nov 18, 2022Morgan Stanley$8.00$10.64-24.81%529.92%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 06, 2024Evercore ISIOutperformupgrade
Nov 05, 2024OppenheimerPerformPerformhold
Nov 05, 2024BarclaysMixedMixedhold
Nov 04, 2024RBC CapitalSector PerformSector Performhold
Oct 23, 2024Wells FargoSector PerformSector Performhold
Oct 23, 2024Wells FargoOverweightOverweighthold
Aug 08, 2024Bank of America SecuritiesBuyupgrade
Jun 18, 2024OppenheimerBuyBuyhold
May 08, 2024Morgan StanleyUnderweightEqual-Weightupgrade
May 08, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.87$-2.74$-2.98$-2.02$-2.88----
Avg Forecast$-1.70$-3.01$-3.05$-2.40$-2.70$-1.39$-1.23$-1.37$-1.27
High Forecast$0.27$0.48$0.64$-1.60$-2.32$-0.89$-0.62$-0.97$-0.33
Low Forecast$-4.41$-7.80$-11.34$-2.69$-3.04$-2.41$-1.83$-1.75$-4.54
Surprise %10.00%-8.97%-2.30%-15.83%6.67%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$90.73M$25.54M$19.71M$78.12M-----
Avg Forecast$85.15M$17.41M$16.59M$21.99M$34.36M$8.72M$5.43M$13.20M$30.22M
High Forecast$189.30M$38.70M$51.31M$50.85M$53.91M$26.01M$16.20M$39.37M$90.13M
Low Forecast$9.21M$1.88M$1.15M$12.42M$3.72M$3.74M$2.33M$5.67M$12.97M
Surprise %6.55%46.75%18.84%255.28%-----

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-109.41M$-185.11M$-204.35M$-153.22M$-237.09M----
Avg Forecast$-98.81M$-203.25M$-226.29M$-153.22M$-210.57M$-144.63M$-93.01M$-103.61M$-96.36M
High Forecast$-72.89M$-162.60M$-181.04M$-122.58M$-176.38M$-67.63M$-46.86M$-73.91M$-24.86M
Low Forecast$-124.73M$-243.89M$-271.55M$-183.86M$-230.88M$-183.12M$-139.15M$-133.32M$-344.75M
Surprise %10.73%-8.92%-9.70%-12.59%----

EDIT Forecast FAQ

Is Editas Medicine stock a buy?

Editas Medicine stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 6 Hold, 2 Sell, and 0 Strong Sell, reflecting a consensus that Editas Medicine is a favorable investment for most analysts.

What is Editas Medicine's price target?

Editas Medicine's price target, set by 19 Wall Street analysts, averages $8 over the next 12 months. The price target range spans from $5 at the low end to $10 at the high end, suggesting a potential 529.92% change from the previous closing price of $1.27.

How does Editas Medicine stock forecast compare to its benchmarks?

Editas Medicine's stock forecast shows a 529.92% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Editas Medicine over the past three months?

  • April 2025: 0% Strong Buy, 26.67% Buy, 60.00% Hold, 0% Sell, 13.33% Strong Sell.
  • March 2025: 0% Strong Buy, 26.67% Buy, 60.00% Hold, 0% Sell, 13.33% Strong Sell.
  • February 2025: 0% Strong Buy, 26.67% Buy, 60.00% Hold, 0% Sell, 13.33% Strong Sell.

What is Editas Medicine’s EPS forecast?

Editas Medicine's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.39, marking a -51.74% decrease from the reported $-2.88 in 2024. Estimates for the following years are $-1.23 in 2026, $-1.37 in 2027, and $-1.27 in 2028.

What is Editas Medicine’s revenue forecast?

Editas Medicine's average annual revenue forecast for its fiscal year ending in December 2025 is $8.72M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $5.43M, followed by $13.2M for 2027, and $30.22M for 2028.

What is Editas Medicine’s net income forecast?

Editas Medicine's net income forecast for the fiscal year ending in December 2025 stands at $-145M, representing a -39.00% decrease from the reported $-237M in 2024. Projections indicate $-93.007M in 2026, $-104M in 2027, and $-96.362M in 2028.